+46.1%
GSK vs NYT
+56.2%
-10.1%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | NYT | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +0.5% | -0.4% | 0.0% |
| 7D | -3.5% | -0.6% | -2.9% | -3.5% |
| 30D | -3.4% | +4.6% | -8.0% | -3.5% |
| 3M | -8.1% | -9.6% | +1.5% | -7.9% |
| 6M | -11.1% | -14.0% | +2.9% | -11.0% |
| YTD | +0.7% | -2.8% | +3.6% | +1.2% |
| 1Y | +20.1% | +15.6% | +4.5% | +20.7% |
| 3Y | +46.1% | +56.3% | -10.2% | +40.3% |
| All | +46.1% | +56.2% | -10.1% | +40.3% |
Cumulative growth
Daily Returns
Daily percentage return beside NYT.
Daily Out/Under-Performance
Portfolio return minus NYT return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × NYT return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded NYT wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling